Published in Gan To Kagaku Ryoho on November 01, 2009
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol (2009) 4.05
Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 3.94
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer (2012) 2.01
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol (2008) 1.88
Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig (2013) 1.70
Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther (2010) 1.39
Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells (2007) 1.35
Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med (2011) 1.31
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res (2002) 1.22
OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest (2007) 1.21
High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology (2002) 1.04
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol (2011) 1.03
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res (2004) 1.01
Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol Ther (2011) 0.99
Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol (2006) 0.99
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist (2012) 0.98
Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. Cancer Sci (2003) 0.98
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med (2008) 0.95
Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res (2005) 0.93
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology (2011) 0.92
Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila. Infect Immun (2005) 0.90
Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol (2006) 0.90
Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol (2012) 0.89
Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol (2008) 0.88
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. Lung Cancer (2013) 0.87
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol (2005) 0.86
Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med (2009) 0.85
Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther (2002) 0.84
[A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)]. Gan To Kagaku Ryoho (2010) 0.81
Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur J Immunol (2003) 0.80
A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer (2006) 0.79
A change in the number of CCSP(pos)/SPC(pos) cells in mouse lung during development, growth, and repair. Respir Investig (2013) 0.79
N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers. Oncogene (2003) 0.78
[Availability evaluation of closed systems by using practical training kits for preparation of antitumor drugs]. Gan To Kagaku Ryoho (2010) 0.76
Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer. J Thorac Oncol (2006) 0.76
A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. J Thorac Oncol (2006) 0.76
Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study. Oncol Lett (2011) 0.75
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation. Cancer Sci (2008) 0.75
[Survey on antiemetic therapy in ambulatory cancer chemotherapy and medical economics for standardization]. Gan To Kagaku Ryoho (2007) 0.75
[Effect of preliminary medication on oxaliplatin hypersensitivity]. Gan To Kagaku Ryoho (2009) 0.75
[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer]. Gan To Kagaku Ryoho (2010) 0.75
[A case of pulmonary Langerhans cell histiocytosis discovered by CT mass screening and followed by bronchoalveolar lavage]. Nihon Kokyuki Gakkai Zasshi (2006) 0.75
Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings. J Thorac Oncol (2008) 0.75
[Surgical treatment outcomes of multimodality therapy for locally recurrent rectal cancer]. Gan To Kagaku Ryoho (2014) 0.75
Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res (2004) 0.75
[A case of gastric cancer treated with modified docetaxel, cisplatin and 5-fluorouracil(mDCF)with ingestion inability]. Gan To Kagaku Ryoho (2012) 0.75
[Standard chemotherapy of solid tumors. 1) Cancers of the respiratory system and breast]. Nihon Naika Gakkai Zasshi (2009) 0.75
[Management of adverse effects of standard regimens for small cell lung cancer]. Nihon Rinsho (2015) 0.75
[Survey on the compliance of patients with continuous infusion of 5-fluorouracil via portable infusion pumps]. Gan To Kagaku Ryoho (2010) 0.75